Polemics of pioglitazone: an appraisal in 2015.

Polemics of pioglitazone: an appraisal in 2015. Expert Rev Endocrinol Metab. 2015 Jul;10(4):447-458 Authors: Singh AK Abstract Pioglitazone is an inexpensive and effective oral drug for the treatment of Type 2 diabetes. It addresses insulin resistance, one of the core pathophysiological defects in Type 2 diabetes, at both the adipose tissue and skeletal muscle level. As a majority of Type 2 diabetics classically exhibit higher insulin resistance, pioglitazone may strike exactly at the Achilles heel in this core pathogenesis. However, with the emerging association of bladder cancer with pioglitazone, French and German regulators were the first to ban or restrict pioglitazone use in 2011. The Indian regulators also suspended pioglitazone, although this ban was revoked within a month. Recently, a 10-year longitudinal study commissioned by US FDA found no association between bladder cancer and pioglitazone. Nevertheless, this controversy created a huge outcry in the medical fraternity. This review article is an overview of the development of this topic and an attempt to provide perspective on this contemporary issue. PMID: 30293494 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research

Related Links:

Publication date: August 2018Source: Trends in Food Science &Technology, Volume 78Author(s): Nevin Sanlier, Buşra Basar Gokcen, Mehmet AltuğAbstractTea is the most widely consumed beverage in the world next to water and is obtained from the leaves Camellia sinensis. In recent years, the potential health benefits and effect mechanisms of tea have attracted a lot of interest. The potential health benefits of tea have been attributed to its various phenolic compounds with unique biological properties found in tea. These phenolic compounds are especially catechins and their derivatives, which constitute at most 30% of th...
Source: Trends in Food Science and Technology - Category: Food Science Source Type: research
Conclusions: Among participants without baseline prediabetes, arsenic exposure was associated with incident diabetes. Low MMA% was cross-sectional and prospectively associated with higher HOMA2-IR. Research is needed to confirm possible interactions of arsenic metabolism with B vitamins and AS3MT variants on diabetes risk. https://doi.org/10.1289/EHP2566 Received: 23 July 2017 Revised: 30 October 2017 Accepted: 7 November 2017 Published: 20 December 2017 Address correspondence to M. Grau-Perez, Columbia University Mailman School of Public Health, 722 W. 168th St., Room 1105, New York, NY 10032. Telephone: 212-342-4712...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
Conclusions: Peroral arsenic has little effect on local airway immune responses to bacteria but compromises respiratory epithelial barrier integrity, increasing systemic translocation of inhaled pathogens and small molecules. https://doi.org/10.1289/EHP1878 Received: 09 March 2017 Revised: 14 August 2017 Accepted: 16 August 2017 Published: 28 September 2017 Address correspondence to M.B. Fessler, National Institute of Environmental Health Sciences, 111 T.W. Alexander Dr., P.O. Box 12233, Maildrop D2-01, Research Triangle Park, NC 27709 USA. Telephone: (919) 541-3701. Email: fesslerm@niehs.nih.gov *Current address: UN...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - Category: Science Source Type: news
Conclusion It seems likely from this research that pioglitazone is linked to an increased risk of bladder cancer, although the overall chances of getting bladder cancer remain very low. While this type of research cannot prove that pioglitazone is the cause of the increased risk of bladder cancer, it is not easy to find a convincing alternative explanation for these results. Previous research has already shown unexpectedly higher levels of bladder cancer among people taking pioglitazone, although other studies had found no such link. However, the size and the care with which this new study was carried out makes it convinc...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Diabetes Medication Source Type: news
Type 2 diabetes has been associated with an increase in the incidence and mortality from many cancers. Understanding the mechanisms underlying Type 2 diabetes, has contributed to the discovery of the potential anti-cancer effects of diabetes treatments. Insulin resistance and hyperinsulinemia precede the development of hyperglycemia and Type 2 diabetes, and may be key factors contributing to the increased cancer risk. Other factors including hyperglycemia, steroid hormonal bioavailability (estrogen and testosterone), insulin-like growth factors, adipokines (leptin and adiponectin) and cytokines may also contribute to cance...
Source: Cancer Prevention Research - Category: Cancer & Oncology Authors: Tags: Metformin Prevention and Treatment Trials: Oral Presentations - Invited Abstracts Source Type: research
ConclusionMetformin has no influence on the risk of UBC compared to SU in type 2 diabetes patients using a new‐user design. This article is protected by copyright. All rights reserved.
Source: British Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Pharmacoepidemiology Source Type: research
Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved as a treatment for type 2 diabetes mellitus (T2DM) in the United States, the European Union and other countries. Dapagliflozin increases renal glucose excretion in an insulin-independent manner, and its mechanism of action is complementary to those of other antidiabetes medications. When used as monotherapy or in combination with other oral antidiabetes medications or insulin, dapagliflozin improves glycemic measures in patients with T2DM. Dapagliflozin treatment is also associated with weight reduction and a decrease in blood pressure, ...
Source: Therapeutic Advances in Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: Reviews Source Type: research
CONCLUSIONS: Dapagliflozin does not provide advantages over pharmacotherapy for DM2. Its lack of experience of use, the absence of significant clinical benefits and its high cost make it necessary to restrict its use. PMID: 25542657 [PubMed - in process]
Source: Farmacia Hospitalaria - Category: Drugs & Pharmacology Authors: Tags: Farm Hosp Source Type: research
More News: Actos | Bladder Cancer | Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Endocrinology | France Health | Germany Health | India Health | Insulin | Oral Cancer | Study